Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POCHI: pembrolizumab with XELOX or FOLFOX-bevacizumab in MSS metastatic colorectal cancer with high immune infiltrate
2024-515788-73-00Phase 2Authorised
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Jul 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab, bevacizumab, oxaliplatin, capecitabine and fluorouracil in colorectal cancer (CRC) and colorectal adenocarcinoma (2 arms), sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoint: 10-month progression-free rate. Planned start Jul 2024; status: authorised.
02
Drugs
03
Conditions
colorectal cancer (CRC)colorectal adenocarcinoma
Beyond the preview
Go deeper on 2024-515788-73-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515788-73-00.